Previous close | 2.3200 |
Open | 2.2950 |
Bid | 2.2300 x 1800 |
Ask | 2.5400 x 900 |
Day's range | 2.2200 - 2.4500 |
52-week range | 0.9600 - 3.8500 |
Volume | |
Avg. volume | 23,927 |
Market cap | 55.594M |
Beta (5Y monthly) | 0.85 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8200 |
Earnings date | 14 May 2024 - 20 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.50 |
TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig,
InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript March 6, 2024 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.16, expectations were $-0.2. InspireMD, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to InspireMD Fourth Quarter and […]
- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CGuard Prime - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company’s C-GUARDIANS II clinical trial of its SwitchGuard™ NPS for Transcarotid Artery Revascularization (TCAR),